Uncategorized
This week in Drug Discovery (1 June – 5 June)
News round-up for 1 June – 5 June by Bruno Quinney, Content Team at DDW.
This week, a cancer drug has demonstrated it could reduce tumours by as much as 55%. Elsewhere, AI has been a recurrent theme in both clinical trials and drug development.
The top stories:
Drug could reduce tumours by 55%, results show
Data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting showed GRWD5769 shrank cancer tumours by a minimum 18%, with as much as 55% of tumours shrunk in non-small cell lung cancer.
Read more…
Obesity drugs could widen health inequalities, warn UK researchers
Without affordable, healthy food and appropriate support, obesity drugs such as semaglutide and tirzepatide could widen health inequalities, say researchers at UCL and the University of Cambridge.
Read more…
Gene test guides more personalised breast cancer treatment
Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, a large international clinical trial led by University College London (UCL) has found.
Trust and regulation holding back AI in clinical trials
A poll from The Pistoia Alliance found that half of respondents agreed trust and regulatory uncertainty were barriers to AI adoption in clinical trials.
First AI drug enters clinical development
CRDMO Quotient Sciences has announced a Phase I study of the AI-formulated drug was initiated at the company’s UK facility following approval from the Medicines and Healthcare products Regulatory Agency (MHRA).
Read more…
The post This week in Drug Discovery (1 June – 5 June) appeared first on Drug Discovery World (DDW).